Belvedere Trading
ATRA icon

Belvedere Trading’s Atara Biotherapeutics ATRA Stock Holding History

Belvedere Trading’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$148 – 807
2023
Q3 		$148 Hold
4
– – ﹤0.01% 618
2023
Q2 		$161 Buy
+4
New +$226 ﹤0.01% 834

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Belvedere Trading's ATRA Position: Q4 2023 in Review

Belvedere Trading sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 1,490 shares — an estimated $55.1K sold.

Belvedere Trading first reported a position in ATRA in Q2 2023 and held it in 2 quarters. The position peaked at $55.1K in Q3 2023. 90 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • Belvedere Trading reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Belvedere Trading sold 1,490 Atara Biotherapeutics shares in Q4 2023, an estimated $55.1K.
  • Belvedere Trading first reported a position in Atara Biotherapeutics in Q2 2023 and held it in 2 quarters.
  • Belvedere Trading's Atara Biotherapeutics position peaked at $55.1K in Q3 2023.
  • 90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.